Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabhalta post-marketing surveillance in PNH (infection risk)
jRCT2031240379Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoints: Occurrence status of infections during Fabhalta treatment and Factors affecting onset of infections. Started Aug 2024; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031240379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240379.